University of Ioannina
Μοριακός έλεγχος RAS μεταλλάξεων του καρκίνου παγκρέατος στο πλάσμα ασθενών με ανεγχείρητο παγκρεατικό καρκίνο με υγρή βιοψία και μελέτη RAS μεταλλάξεων, τροποποιητών RAS σηματοδότησης, ρύθμισης εξωκύττωσης νουκλεϊκών οξέων στον πρωτοπαθή όγκο και της κλωνικής αιμοποίησης: μια προοπτική μελέτη παρατήρησης
Abstract
dc:descriptionIntroduction: Pancreatic ductal adenocarcinoma is a fatal disease with a poor prognosis, with an increasing incidence every year worldwide. 5-year overall survival remains lower than 10%. Despite new emerging therapies for locally advanced and metastatic PDAC (NALIRIFOX, FOLFIRINOX, Abraxane/Gemcitabine), reliable prognostic and predictive biomarkers with established clinical utility are lacking. Recent advancements in the effectiveness of current chemotherapy combinations have led to objective response rates of 20-30% in metastatic disease and an estimated median survival of 8-12 months. In locally advanced and metastatic PDAC, a reliable biomarker with prognostic or early predictive value would allow the de-escalation or intensification of treatment according to its efficacy and enable early therapy modifications if deemed ineffective. Since pancreatic cancer harbors KRAS exon 2 or exon 3 mutations (codons 12, 13, 61) in 90% of cases, KRAS mutation in circulating tumor DNA, the detection of KRAS mutations with liquid biopsy may indicate disease burden, prognosis, and treatment response. Furthermore, the agreement or lack thereof regarding the presence of RAS mutation in the tissue (primary pancreatic cancer) is of exceptional interest. Aim: In light of the above, the primary objective of this study is to detect mutational burden in patients with unresectable and metastatic pancreatic cancer and determine whether the change before and after chemotherapy can serve as an early prognostic biomarker of treatment response. Additionally, the study aims to assess the utility of sequential liquid biopsies and standard tissue analysis to customize therapeutic strategy, potentially offering predictive value for therapeutic decision-making. Methods: Plasma samples from patients with unresectable and metastatic ductal adenocarcinoma of the pancreas were collected before the initiation of chemotherapy and 4-6 weeks later, from the University Hospital of Ioannina, the General Oncology Hospital of Kifisia “Agii Anargyroi,” and the General Hospital of Patras “Agios Andreas.” Clinical data were extracted from patients’ medical records. Analysis was conducted for 34 mutations in the KRAS and NRAS genes (codons 12, 13, 59, 61, 117, 146) using BEAMing Digital PCR, a high-sensitivity technique enabling quantification of mutant alleles in plasma (Mutant Allele Fraction, MAF). Corresponding tissue mutations were analyzed using allele-specific RT-PCR on the Roche Cobas platform. Mutation analysis was also carried out using the NGS method. Mutations were detected with NGS in a subset of 28 patients. Through NGS, the following gene mutations were examined: KRAS, NRAS, BRAF, EGFR, ERBB2, PIK3CA, MAD4, TP53, APC, and AKT1.Results: The presence of KRAS mutations in pre-treatment samples was estimated at 77%. The most frequently detected KRAS mutations via liquid biopsy were KRAS G12D and KRAS G12V, alongside mutations in TP53 and NRAS. Comparison between KRAS mutations in tissue, the standard method for molecular testing, and plasma revealed a positive percent agreement (PPA) of 87%, a negative percent agreement (NPA) of 50%, and an overall percent agreement (OPA) of 85%. There was an 82% change in mutation burden between the pre-treatment sample and the sample taken 4-6 weeks after treatment in the overall population. The proportion of patients without KRAS mutations increased from 39% in the initial pre-treatment sample to 61% in the post-treatment sample, indicating treatment response. The median progression-free survival (mPFS) was prolonged (11 months) for patients with stable mutational burden versus 9.8 months for those with a reduced mutational load. A statistically significant difference was found in survival between patients with stable mutational status and those with varying mutational burden. There was also a statistically significant association between changes in mutational burden (reduction or increase) and imaging response and progression, respectively. There was concordance between mutational burden changes (increase-decrease) and corresponding variations in serum biomarkers CA 19-9 and CEA. Conclusions: The results of the present study support the initial hypothesis that the detection of RAS mutations plays a significant prognostic role in patients with unresectable and metastatic PDAC. Specifically, their change (either decrease or increase) before and after the administration of chemotherapy is directly linked to the clinical and imaging response of the patients. Consequently, using liquid biopsy to detect RAS mutations can play a significant role, both prognostic and predictive, in monitoring the progress of patients with unresectable and metastatic pancreatic adenocarcinoma. However, additional results from randomized clinical trials are required to establish liquid biopsy as a procedure for use in everyday clinical practice. This study adequately supports for the rationale for further clinical trials to be conducted.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkoura, Stefania
- Γκούρα, Στεφανία
Subjects
dc:subject × 20- Υγρή βιοψία
- Καρκίνος παγκρέατος
- RAS μεταλλάξεις
- Μεταστατικός καρκίνος παγκρέατος
- Αλληλούχιση επόμενης γενιάς
- Ψηφιακή αλυσιδωτή αντίδραση πολυμεράσης
- Πάγκρεας
- Ογκολογία
- Pancreatic adenocarcinoma
- Liquid biopsy
- RAS mutations
- Next generation sequencing (NGS)
- BEAMing Digital PCR
- Metastatic pancreatic adenocarcinoma
- Pancreas
- Oncology
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Clinical Medicine
- Medical and Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59039